Obstructive Sleep Apnea vs. Central Sleep Apnea

Human respiration during sleep is a complex neurobiological and mechanical process. It requires seamless coordination between central metabolic respiratory networks in the brainstem and the muscular conduits of the upper airway. When this homeostatic equilibrium fails, sleep-related breathing disorders emerge. These disorders disrupt restorative rest, impair blood gas chemistry, and destabilize systemic physiology. At the center of sleep medicine are two distinct clinical entities: Obstructive Sleep Apnea (OSA) and Central Sleep Apnea (CSA). While both conditions manifest as periodic breathing cessations during sleep, their underlying mechanics, biological drivers, and clinical management strategies differ substantially.

Historically, the medical community frequently conflated these conditions under broad, non-specific labels such as “Pickwickian syndrome” or generalized sleep-induced asphyxia. Early twentieth-century clinicians observed the devastating sequelae of nocturnal asphyxiation—polycythemia, daytime somnolence, right ventricular failure, and sudden nocturnal death—without possessing the physiological instrumentation required to parse structural airway collapse from neurological ventilatory failure. It was not until the emergence of modern clinical polysomnography in the late 1960s and 1970s, pioneered by researchers such as Elio Lugaresi, Christian Guilleminault, and Colin Sullivan, that the fundamental divide between mechanical obstruction and neural ventilatory instability was clearly established.

Today, understanding the distinct profiles of Obstructive Sleep Apnea and Central Sleep Apnea is essential for clinicians across pulmonology, cardiology, neurology, and internal medicine. The misdiagnosis of one for the other can lead to ineffective interventions, ongoing cardiovascular stress, and, in certain clinical subsets, increased mortality. This article provides an exhaustive, comparative analysis of Obstructive Sleep Apnea and Central Sleep Apnea. It examines their basic biophysics, clinical presentations, diagnostic signatures, and targeted therapeutic options.

1. Introduction to Sleep-Related Breathing Disorders

1.1 Defining the Sleep Apnea Spectrum

Sleep-disordered breathing encompasses a broad spectrum of pathological conditions characterized by abnormal respiratory patterns, inadequate ventilation, and disrupted sleep architecture. As categorized by the American Academy of Sleep Medicine (AASM) in the International Classification of Sleep Disorders, Third Edition (ICSD-3), this spectrum extends from benign primary snoring and Upper Airway Resistance Syndrome (UARS) to life-threatening forms of Obstructive Sleep Apnea, hypercapnic central hypoventilation, and non-hypercapnic periodic breathing. The common thread linking these disorders is their capacity to disrupt the physiological restoration of sleep. However, the precise point of failure within the human respiratory apparatus separates the spectrum into distinct mechanical and neurological phenotypes.

The core mechanical division lies between anatomical airway collapse and neurological ventilatory failure. In Obstructive Sleep Apnea, the structural conduit of the pharynx succumbs to closing pressures generated within the thorax, leading to physical obstruction despite persistent, often violent, efforts to breathe. In contrast, Central Sleep Apnea represents a failure of the brain’s metabolic ventilatory control system. In CSA, the central neural command to initiate diaphragmatic and intercostal contraction is transiently withdrawn or suppressed, resulting in respiratory pauses characterized by a complete absence of physical effort. This fundamental distinction—the presence versus the absence of neuro-muscular ventilatory drive—defines the clinical division between these two entities.

The systemic implications of these recurrent respiratory pauses are profound. Both conditions subject the human body to cyclical bouts of intermittent hypoxia, reoxygenation injury, acute hypercapnia, systemic blood pressure surges, and sleep fragmentation. These nocturnal insults trigger widespread endothelial dysfunction, increase reactive oxygen species (ROS) production, upregulate inflammatory cascades via nuclear factor kappa B (NF-κB), and promote persistent sympathetic overdrive. Over time, these molecular perturbations translate into severe end-organ morbidity, including accelerated atherosclerotic vascular disease, drug-resistant hypertension, cardiac arrhythmias, metabolic dysregulation, and neurocognitive impairment.

From an epidemiological standpoint, sleep-related breathing disorders represent a major global public health challenge. Groundbreaking epidemiological research, such as the global analysis published by Benjafield et al. in The Lancet Respiratory Medicine (2019), estimates that nearly one billion adults aged 30 to 69 years worldwide suffer from obstructive sleep apnea, with almost 425 million experiencing moderate to severe disease requiring active intervention. Central sleep apnea, while less prevalent in the general population, occurs in high concentrations within vulnerable clinical cohorts. It affects up to 30% to 50% of patients with chronic congestive heart failure and significant numbers of patients with end-stage renal disease or neurological trauma. Despite these alarming figures, the burden of undiagnosed sleep apnea remains exceptionally high, with an estimated 80% of affected individuals remaining undiagnosed in modern healthcare systems.

1.2 Why Obstructive and Central Sleep Apnea Are Frequently Conflated

In routine clinical practice, Obstructive Sleep Apnea and Central Sleep Apnea are frequently conflated due to their overlapping daytime presentations. Patients suffering from either disorder present with pervasive, debilitating neurocognitive symptoms. Chief among these is excessive daytime sleepiness (EDS), often quantified through the Epworth Sleepiness Scale (ESS). Both OSA and CSA cause repetitive microarousals—transient awakenings lasting 3 to 15 seconds that fragment sleep architecture and eliminate restorative slow-wave (N3) and rapid eye movement (REM) sleep stages. Consequently, patients with either condition wake with profound exhaustion, executive dysfunction, memory deficits, mood lability, and morning headaches.

This clinical ambiguity is compounded by the frequent co-occurrence of both phenotypes within individual patients. Sleep apnea is rarely an all-or-nothing binary phenomenon; rather, it exists along a dynamic pathophysiological continuum. A patient may present with primary mechanical airway collapse, but upon exposure to positive airway pressure therapy, unmask an underlying instability in central ventilatory control—a condition known as treatment-emergent central sleep apnea or complex sleep apnea. Furthermore, individual respiratory events may possess mixed morphology, initiating with a central cessation of effort and concluding with obstructive respiratory struggle as the pharyngeal walls collapse during the pause. Such presentations blur the diagnostic boundary for general practitioners relying solely on clinical history.

Historical diagnostic workflows have perpetuated this confusion. For decades, non-specialist clinical encounters relied heavily on blunt, non-specific nocturnal symptoms: reports of restless sleep, nocturia, and generalized fatigue. Even bedpartner reports can be misleading. While loud, disruptive snoring and observed snorting pauses are classic hallmarks of OSA, patients with Cheyne-Stokes breathing in central sleep apnea may also present with secondary hyperpneic breathing that mimics obstructive gasping. Without objective physiological tracing of thoracoabdominal motion, airflow thermistry, and nasal pressure manometry, distinguishing between an airway that cannot open and a brain that is not signaling the lungs to breathe remains challenging.

2. Understanding Obstructive Sleep Apnea (OSA)

2.1 Pathophysiology and Anatomical Airway Collapsibility

The human pharynx is an anatomical marvel designed to serve the conflicting functions of vocalization, deglutition, and respiration. Unlike the lower respiratory tract, which is supported by rigid cartilaginous rings, the pharynx is a collapsible muscular tube devoid of rigid structural reinforcement. Its patency depends entirely on the active contraction of surrounding pharyngeal dilator muscles, primarily the genioglossus, the tensor veli palatini, and the hyoid apparatus. During wakefulness, elevated neuromuscular tone easily counteracts the subatmospheric collapsing pressures generated inside the airway lumen during inspiration. During sleep, however, the central nervous system downregulates motor output from the hypoglossal and other cranial motor nuclei, predisposing anatomically vulnerable individuals to airway collapse.

The biomechanical behavior of the upper airway is accurately modeled by the Starling resistor concept, which describes flow through a collapsible conduit. Within this framework, pharyngeal collapsibility is quantified by the pharyngeal critical closing pressure, or Pcrit. The Pcrit represents the intraluminal pressure at which the upper airway completely collapses. In healthy individuals with resilient airway geometry, Pcrit remains highly negative (often below -8 cm H₂O), meaning the airway remains patent even in the face of significant negative inspiratory pressures. In individuals with mild-to-moderate OSA, Pcrit shifts closer to atmospheric levels (-4 to 0 cm H₂O), and in patients with severe obstructive disease, it becomes positive (+2 to +5 cm H₂O), indicating an airway that spontaneously collapses the moment neuromuscular tone is lost at sleep onset.

When the pharyngeal walls appose, the diaphragm and external intercostal muscles continue to contract, generating increasingly negative intrathoracic pressures—often dropping to -40 to -80 cm H₂O in a futile attempt to draw air past the physical barrier. This phenomenon, known physiologically as a classic Müller maneuver, exerts extreme mechanical shear stress across the thoracic cavity. It dramatically increases left ventricular transmural pressure, elevates afterload, impairs cardiac filling, and induces right ventricular strain by pulling venous blood rapidly into the right atrium. As the obstruction persists, alveolar ventilation ceases, initiating an acute cascade of arterial hypoxemia, systemic carbon dioxide retention (hypercapnia), and respiratory acidosis.

This progressive asphyxia stimulates both central chemoreceptors in the brainstem and peripheral chemoreceptors in the carotid bodies. These receptors trigger an escalating crescendo of sympathetic efferent nerve activity. Ultimately, this intense autonomic surge forces a transient cortical microarousal, rousing the patient from deeper sleep into a lighter stage or wakefulness. With arousal, a burst of motor output reaches the hypoglossal nerve, the genioglossus contracts vigorously, and the pharyngeal airway snaps open, producing a loud compensatory gasp, snort, or snore. The patient hyperventilates to clear the accumulated carbon dioxide and reoxygenate the blood, only to slip back into deeper sleep, repeating the cycle anywhere from dozens to hundreds of times each night.

2.2 Etiology, Risk Factors, and Predisposing Phenotypes

The etiology of Obstructive Sleep Apnea is multifactorial, driven by an interplay of anatomical predispositions and non-anatomical physiological phenotypes. Over the past decade, sleep researchers have conceptualized OSA pathophysiology through the “PALM” scale model. This model isolates the four principal physiological traits governing disease expression:

• P: Pharyngeal collapsibility (Pcrit)
• A: Arousal threshold (the ease with which respiratory stimulation wakes the brain)
• L: Loop gain (the sensitivity and responsiveness of the ventilatory feedback system)
• M: Muscle responsiveness (the ability of the upper airway dilators to recruit and restore patency during sleep)

While non-anatomical traits govern clinical presentation, anatomical compromise remains the primary foundation of obstructive disease.

Craniofacial morphology plays a direct role in upper airway dimensions. Skeletal variations that reduce the volume of the bony enclosure surrounding the pharynx dramatically increase closing tendencies. Patients presenting with retrognathia (a posterior displacement of the mandible) or micrognathia (an abnormally small jaw) experience posterior displacement of the tongue base directly into the retroglossal airway space. Similarly, maxillary constriction with a high, narrow, arched hard palate encroaches upon both the nasal cavity and the retro-palatal pharyngeal space. An inferiorly displaced hyoid bone, often an inherited morphometric trait, elongates the pharyngeal tube, making it structurally more susceptible to collapse under the laws of fluid dynamics (Poiseuille’s law). Furthermore, soft tissue hypertrophy, including adenotonsillar enlargement (the leading driver of OSA in pediatric populations), macroglossia, and an elongated, thickened uvula, severely crowds the oropharyngeal lumen.

Excess adiposity represents the most prevalent and modifiable environmental risk factor for obstructive sleep apnea. Weight gain compromises airway stability through dual mechanical mechanisms. First, adipose tissue is directly deposited within the parapharyngeal fat pads flanking the pharyngeal lateral walls and within the tongue musculature itself. Increased tongue volume, driven by intramuscular fat deposition, dramatically expands the mass that must be displaced forward by the genioglossus muscle during sleep. A thick neck circumference—exceeding 17 inches (43 cm) in biological males or 16 inches (40 cm) in biological females—serves as a strong clinical surrogate for this localized mechanical crowding. Second, visceral adiposity within the abdomen and chest wall reduces functional residual capacity (FRC). Reduced lung volumes decrease caudal tracheal traction forces—the physical anchoring tug exerted by the lungs and mediastinum on the trachea—thereby increasing pharyngeal wall collapsibility.

Demographic factors heavily influence OSA incidence. Biological males exhibit a two-to-threefold higher risk compared to premenopausal females, an disparity driven by male patterns of visceral and upper-body fat distribution, larger soft palate lengths, and differences in pharyngeal collapsibility dynamics. However, this protective female advantage dissipates rapidly following menopause, when declining levels of circulating progesterone (a potent natural respiratory and genioglossus stimulant) and estrogen cause pharyngeal collapsibility in women to mirror male patterns. Advanced age acts as an independent risk factor across both sexes, driven by age-related loss of collagen elasticity within pharyngeal tissues, gradual neuromuscular coordination decay, and increased rates of rostral fluid shift. This fluid shift involves gravity-dependent dependent edema from the lower extremities mobilizing cephalad during recumbency, pooling in the soft tissues of the neck and narrowing the airway. Finally, exogenous agents such as alcohol, benzodiazepines, and muscle relaxants aggravate the disorder by selectively suppressing hypoglossal motor output, paralyzing protective dilator reflexes, and blunting the cortical arousal threshold.

2.3 Clinical Presentation and Diagnostic Identification

The classic clinical presentation of Obstructive Sleep Apnea centers around a cardinal triad: loud, chronic, disruptive snoring; witnessed pauses in nocturnal breathing; and abrupt awakenings accompanied by gasping, snorting, or choking sensations. Bedpartners frequently describe an agonizing cycle in which rhythmic, escalating snoring suddenly cuts off into a deathly silence lasting 20 to 60 seconds, terminated by a violent convulsive body jerk and an explosive snort as the airway re-opens. While snoring is present in up to 95% of patients with severe OSA, its absence does not completely rule out the diagnosis, particularly in elderly populations or individuals with predominantly hypopneic, rather than fully apnoeic, airway collapse.

The daytime consequences of this nocturnal struggle are extensive. Patients report unrefreshing sleep regardless of time spent in bed, accompanied by intense morning brain fog, xerostomia (dry mouth resulting from open-mouth breathing), and frontotemporal tension headaches caused by nocturnal hypercapnic vasodilation of cerebral vessels. Nocturia is another prominent, yet frequently overlooked, diagnostic symptom. The massive negative intrathoracic pressure swings generated during obstructive efforts stretch the right and left atria, artificially signaling volume overload to the myocardium. In response, cardiomyocytes release atrial natriuretic peptide (ANP), which acts directly on the renal collecting ducts to induce nocturnal sodium excretion and diuresis, driving patients out of bed multiple times each night.

Objective diagnostic identification requires comprehensive physiological monitoring. The definitive diagnostic gold standard is Type 1 in-laboratory, attended Polysomnography (PSG). During overnight polysomnography, the pathognomonic hallmark of an obstructive apnea is the persistent continuation, or paradoxical amplification, of thoracoabdominal respiratory effort throughout the entire duration of absent airflow. Airflow is precisely captured using a combination of an oronasal thermal sensor (to detect complete apneas) and a nasal pressure transducer (to identify subtle hypopneas via flow limitation flattening). Respiratory effort is measured using dual respiratory inductance plethysmography (RIP) belts placed snugly around the rib cage and the abdomen.

In OSA, when the pharynx occludes, the RIP tracings reveal an out-of-phase, asynchronous, or “paradoxical” motion: as the chest wall moves outward to generate inspiration, the abdominal wall moves inward due to the downward pull of the diaphragm against an occluded airway, creating a seesaw mechanical profile. The severity of the disorder is quantified using the Apnea-Hypopnea Index (AHI), which represents the total number of apneas and hypopneas scored per hour of total sleep time:

• Normal Sleep: AHI < 5 events per hour
• Mild OSA: AHI 5 to 14.9 events per hour (accompanied by validated clinical symptoms)
• Moderate OSA: AHI 15 to 29.9 events per hour
• Severe OSA: AHI ≥ 30 events per hour

To fully capture physiological strain, the AHI is paired with the Oxygen Desaturation Index (ODI), which tracks the frequency of arterial oxygen saturation drops of ≥3% or ≥4% from baseline. Together, they quantify the intermittent hypoxic and mechanical toll on the patient’s cardiovascular system.

3. Understanding Central Sleep Apnea (CSA)

3.1 Pathophysiology and Ventilatory Control Instability

Unlike Obstructive Sleep Apnea, where the respiratory motor drive struggles against a closed door, Central Sleep Apnea is fundamentally a disorder of ventilatory control neurobiology. In CSA, the central command center in the brainstem fails to send rhythmic signals to the phrenic and intercostal nerves, leading to an absence of diaphragmatic excursion, an absence of chest wall movement, and an immediate cessation of alveolar ventilation. The airway itself may remain open, but the neurological pump driving air exchange is temporarily shut down.

Metabolic control of breathing during non-REM (NREM) sleep is governed by autonomic chemoreceptor feedback loops located in the ventrolateral medulla (central chemoreceptors) and the bifurcation of the common carotid arteries (peripheral carotid body chemoreceptors). These sensors continuously monitor the partial pressure of arterial carbon dioxide (PaCO₂) and hydrogen ion concentrations ([H⁺]). During wakefulness, breathing is maintained by both metabolic feedback and an active, descending cortical “wakefulness drive to breathe.” This wakefulness drive ensures that ventilation continues even if PaCO₂ drops significantly. However, upon transitioning into NREM sleep, this cortical feedforward drive is switched off. Respiration becomes dependent solely on the metabolic autonomic control system, unmasking a critical physiological boundary known as the apneic threshold.

The apneic threshold represents the specific level of PaCO₂ below which respiratory rhythm generation in the pre-Bötzinger complex completely stops. In healthy individuals, the normal waking PaCO₂ sits around 40 mm Hg, and the sleep apneic threshold is set 2 to 6 mm Hg below this baseline. When an individual hyperventilates—whether triggered by an arousal, pulmonary congestion, or hypoxia—their PaCO₂ drops. If the PaCO₂ falls below this critical threshold, central respiratory drive immediately ceases, inducing a central apnea. The apnea persists until metabolic cellular respiration produces sufficient carbon dioxide to raise the PaCO₂ back above the threshold, at which point breathing resumes.

The stability of this ventilatory control system is evaluated through engineering control theory using the concept of loop gain. Loop gain is a dimensionless ratio that reflects the magnitude of the ventilatory response relative to an initial disturbance. A system with a low loop gain (<1.0) is stable and inherently self-dampening: a small disturbance is corrected smoothly without overshooting. Conversely, a system with a high loop gain (>1.0) is unstable, hyper-reactive, and prone to sustained oscillations. Loop gain is composed of three components:

• Controller Gain: The sensitivity of the chemoreceptors (how vigorously they respond to a 1 mm Hg change in PaCO₂).
• Plant Gain: The efficiency of the lungs and chest wall in clearing CO₂ from the blood per unit of hyperventilation.
• Feedback Delay: The circulatory transit time required for oxygenated and carbon dioxide-laden blood to travel from the pulmonary capillaries to the carotid bodies and brainstem.

When controller gain is pathologically elevated, or when prolonged circulatory transit times delay chemical feedback to the brain, the respiratory control loop falls into severe, cyclic oscillations, generating the rhythmic central pauses that characterize CSA.

3.2 Etiologies and Clinical Subtypes of CSA

Central Sleep Apnea is not a single disease, but an umbrella term for several distinct clinical phenotypes, each with unique systemic drivers. The most clinically prominent subtype is Central Sleep Apnea with Cheyne-Stokes Breathing (CSA-CSB). This condition is observed in up to half of all patients with symptomatic congestive heart failure with reduced ejection fraction (HFrEF) and patients recovering from extensive cerebrovascular accidents (ischemic or hemorrhagic strokes). The pathophysiology of CSA-CSB is driven by two factors: prolonged circulatory delay and pulmonary congestion.

In heart failure, a depressed left ventricular ejection fraction significantly slows blood transit time from the pulmonary bed to the carotid chemoreceptors, increasing feedback delay. Concurrently, elevated left ventricular end-diastolic filling pressures cause pulmonary capillary congestion, which stimulates pulmonary vagal unmyelinated J-receptors. This stimulation triggers chronic, reflexive hyperventilation. This hyperventilation drives baseline resting PaCO₂ downward, leaving the patient hovering just above their apneic threshold. When a small arousal or change in sleep depth triggers a brief burst of hyperventilation, the PaCO₂ falls below the apneic threshold. Because of the prolonged circulatory delay, the brainstem does not realize this until seconds later. A central apnea is triggered, CO₂ builds up, and when the blood eventually reaches the carotid bodies, the system overreacts with an exaggerated hyperpneic ventilatory response. This creates the classic, repeating crescendo-decrescendo breathing pattern of Cheyne-Stokes respiration.

A second major subtype is High-Altitude Periodic Breathing. This form occurs in healthy individuals ascending to elevations typically above 8,000 to 10,000 feet (2,500 to 3,000 meters). The low ambient barometric pressure decreases the inspired partial pressure of oxygen (PiO₂), inducing acute arterial hypoxemia. This triggers the Hypoxic Ventilatory Response (HVR) via the carotid bodies, causing vigorous hyperventilation. While hyperventilation improves oxygenation, it clears large amounts of carbon dioxide from the blood, inducing hypocapnia and systemic respiratory alkalosis. During subsequent NREM sleep, this hypocapnia drives PaCO₂ below the apneic threshold, causing central apneas. The cycle only stabilizes once acclimatization occurs through renal bicarbonate excretion, which restores arterial pH toward normal.

A third subtype is Drug-Induced Central Sleep Apnea, driven by chronic opioid therapy. Opioids cross the blood-brain barrier and bind directly to μ-opioid receptors located on respiratory rhythm-generating neurons within the pre-Bötzinger complex and the parabrachial/Kölliker-Fuse complex in the dorsolateral pons. This binding depresses central ventilatory responsiveness to hypercapnia and disrupts the regular pacemaking of breathing. The resulting respiratory pattern, often termed Ataxic or Biot’s breathing, is characterized by irregular, erratic tidal volumes, unpredictable central pauses, and variable hypopneic events. Unlike Cheyne-Stokes breathing, opioid-induced central sleep apnea lacks a rhythmic crescendo-decrescendo pattern and can progress to life-threatening awake and asleep hypercapnic hypoventilation.

Finally, Idiopathic Primary Central Sleep Apnea is a rare clinical subtype diagnosed in the absence of heart failure, stroke, altitude, or drug use. Patients with idiopathic CSA possess an inherently elevated central chemoreceptor sensitivity (high controller gain). Their respiratory centers overreact to minimal rises in carbon dioxide during wake-sleep transitions, inducing repeated hyperpneas that wash out CO₂, drop levels below the apneic threshold, and trigger recurrent central respiratory arrests.

3.3 Clinical Presentation and Objective Findings

The clinical presentation of Central Sleep Apnea contrasts sharply with that of Obstructive Sleep Apnea. While OSA patients are typically brought to the clinic by partners exhausted by loud, wall-shaking snoring, patients with CSA frequently seek medical care on their own due to severe sleep-maintenance insomnia. They describe an inability to stay asleep, waking repeatedly throughout the night with sensations of suffocation, paroxysmal nocturnal dyspnea, or unexplained surges of panic. These awakenings occur not during the apnea itself, but during the hyperpneic recovery phase, when deep, rapid breathing and sympathetic activation shake the patient out of NREM sleep.

Because pure central sleep apnea involves no mechanical airway narrowing, classic disruptive snoring is often absent. Patients, their bedpartners, and their physicians may mistakenly attribute their frequent awakenings to primary anxiety, gastroesophageal reflux, panic disorders, or intrinsic cardiac decompensation. Furthermore, daytime sleepiness, while present, is often less pronounced in CSA than in OSA. Instead, CSA patients report chronic daytime fatigue, emotional exhaustion, exercise intolerance, and severe cognitive fragmentation. In populations with heart failure, the emergence of CSA is often marked by worsening New York Heart Association (NYHA) functional class, refractory fluid retention, and sudden ventricular arrhythmias, rather than obvious daytime somnolence.

On polysomnography, Central Sleep Apnea displays distinct physiological signatures:

• Airflow, measured by the diagnostic oronasal thermal sensor and nasal pressure transducer, drops by ≥90% from baseline for a duration of at least 10 seconds.
• Concurrently, the RIP belts monitoring the rib cage and abdomen flatline, confirming a complete absence of respiratory effort throughout the event.
• There is no paradoxical chest-wall motion, no inward abdominal sucking, and no muscle activity on intercostal electromyography.

The cessation of breathing is quiet and structurally still.

In Cheyne-Stokes breathing, the polysomnographic pattern displays a rhythmic crescendo-decrescendo morphology. The respiratory cycle begins with shallow, barely perceptible breaths that gradually increase in depth (the crescendo) until reaching a hyperpneic peak. The breaths then steadily taper downward (the decrescendo) into a central apnea or hypopnea. The duration of this entire cycle—from the start of one crescendo to the end of the next central pause—is prolonged, often lasting 60 to 90 seconds or more. This long cycle length directly mirrors the delayed circulation time of a failing left ventricle. The nadir of arterial oxygen desaturation is similarly delayed, registering on pulse oximetry well after the central apnea has terminated and the hyperpneic phase has already begun.

4. Key Differences Between Obstructive and Central Sleep Apnea

4.1 Etiological and Mechanical Divergence

The fundamental divergence between Obstructive Sleep Apnea and Central Sleep Apnea lies in the distinction between physical mechanics and neurological control. OSA is an anatomical, mechanical failure of a dynamic conduit. The upper airway collapses under physical forces dictated by fluid dynamics, intraluminal suction, tissue mass, and muscular fatigue. The brain continues to send motor commands to the diaphragm, but the physical pathway is blocked. CSA, on the other hand, is a failure of chemical feedback control. The physical airway is typically patent, but the brainstem transiently stops transmitting the motor commands required to breathe.

This biomechanical difference is clearly illustrated by the opposing motions of the chest and abdomen during polysomnography. In OSA, the patient’s respiratory muscles battle against an occlusive barrier. The chest wall expands outward to generate negative intrathoracic suction, but because no air enters, the abdominal wall is drawn inward, creating the hallmark asynchronous, “paradoxical” rocking motion of obstructive asphyxiation. In pure CSA, the motor nerves are silent. The diaphragm, external intercostals, and abdominal musculature remain completely relaxed. The chest and abdomen remain motionless, with no phase difference because there is no movement at all.

4.2 Symptomatic and Demographic Differences

The demographic profiles and clinical features of OSA and CSA point to different patient populations. OSA is tied closely to metabolic health and anatomy. It is strongly associated with elevated Body Mass Index (BMI > 30 kg/m²), visceral obesity, increased neck circumference, male sex, postmenopausal status, and structural craniofacial variations. Its clinical profile is defined by loud, turbulent snoring, morning xerostomia, observed choking spells, and daytime hypersomnolence. Many patients remain unaware of their nocturnal struggle, with the sleeping partner acting as the primary historian.

In contrast, CSA is tied to systemic cardiorespiratory and neurological disease. Pure CSA frequently presents in patients who are normal-weight or even cachectic, particularly those with advanced heart failure. It affects individuals with structural central nervous system pathology, such as brainstem infarctions, Chiari malformations, or cervical spine injuries, as well as those on chronic opioid regimens for non-malignant pain management. The symptomatic presentation is defined by fragmented sleep, sleep-maintenance insomnia, night sweats, paroxysmal nocturnal dyspnea, and profound morning fatigue rather than snoring. CSA patients are often keenly aware of their fitful sleep, describing recurring sensations of gasping awake or feeling their heart race as they drift off.

4.3 Polysomnographic and Measurement Differentiation

Polysomnography provides the objective baseline data required to differentiate these two disorders. The primary distinguishing metric on a polysomnogram is the presence or absence of thoracoabdominal effort during periods of reduced airflow. In OSA, dual RIP bands register active, high-amplitude excursions that are 180 degrees out of phase, accompanied by flattening of the nasal pressure cannula tracing—a classic indicator of flow limitation. In CSA, the RIP band signals drop to near-zero amplitude, indicating a synchronized cessation of muscular effort without flow limitation.

Baseline arterial carbon dioxide tension (PaCO₂) also differs between the two conditions. In patients with uncomplicated, non-hypercapnic CSA (such as Cheyne-Stokes breathing or altitude-induced CSA), baseline waking and sleeping PaCO₂ is typically low (hypocapnia, often PaCO₂ < 35 mm Hg) due to chronic hyperventilation. In patients with severe, long-standing OSA, baseline waking PaCO₂ is usually normal (eucapnia, 38 to 42 mm Hg). If obesity hypoventilation syndrome (OHS) develops alongside OSA, daytime hypercapnia emerges (PaCO₂ > 45 mm Hg), with end-tidal or transcutaneous CO₂ monitoring showing sustained retention throughout the night. Finally, the timing of cortical microarousals differs: in OSA, the arousal occurs at the end of the obstructive pause to facilitate airway opening; in CSA-CSB, the arousal typically occurs at the peak of the hyperpneic crescendo phase, driven by intense metabolic stimulation and deep ventilatory mechanics.

Pathophysiological & Clinical Dimension	Obstructive Sleep Apnea (OSA)	Central Sleep Apnea (CSA)
Primary Mechanism	Recurrent physical narrowing or complete anatomical collapse of the pharyngeal airway.	Transient withdrawal of rhythmic central ventilatory motor output from the brainstem.
Anatomical Site of Defect	Velopharynx, oropharynx, and/or hypopharynx (extranodal upper airway).	Medullary respiratory centers (pre-Bötzinger complex, retrotrapezoid nucleus) and chemoreceptor reflex loops.
Thoracoabdominal Effort During Apnea	Present, persistent, and typically increased; characterized by paradoxical out-of-phase movement.	Absent; complete cessation of both thoracic and abdominal movement (flatline tracings).
Classic Nocturnal Symptoms	Loud, chronic, disruptive snoring; witnessed gasping, choking, and snorting.	Recurrent nighttime awakenings, paroxysmal nocturnal dyspnea, and fitful, non-restorative sleep; snoring often absent.
Primary Daytime Presentation	Severe excessive daytime sleepiness (high Epworth Sleepiness Scale scores), morning dry mouth.	Chronic fatigue, sleep-maintenance insomnia, daytime cognitive exhaustion, exercise intolerance.
Primary Polysomnographic Hallmark	Cessation of airflow accompanied by ongoing, escalating respiratory effort signals.	Simultaneous cessation of airflow and respiratory effort channels across the event.
Biophysical Modeling Framework	Starling resistor mechanics, critical closing pressure (Pcrit), Poiseuille resistance.	Engineering feedback control theory, loop gain (controller gain, plant gain, circulatory delay).
Predominant Body Habitus	Typically elevated BMI (>30 kg/m2), visceral adiposity, large neck circumference.	Variable; frequently normal-weight, non-obese, or cachectic in severe heart failure cohorts.
Dominant Comorbid Associations	Essential hypertension, metabolic syndrome, Type 2 diabetes, coronary artery disease.	Congestive heart failure (HFrEF/HFpEF), atrial fibrillation, stroke, chronic kidney disease, chronic opioid use.
Baseline Arterial Carbon Dioxide	Typically eucapnic (38-42 mm Hg); hypercapnic only if accompanied by Obesity Hypoventilation.	Often hypocapnic (<35 mm Hg) in non-hypercapnic CSA; hypercapnic in opioid-induced/neuromuscular hypoventilation.
Response to Standard CPAP	Highly effective; acts as a pneumatic splint to physically open the occluded pharyngeal conduit.	Variable and often poor; may worsen central apneas by lowering PaCO2 via over-ventilation.
First-Line Treatment Modalities	Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Devices, positional therapy.	Optimization of underlying medical pathology (e.g., GDMT for heart failure), ASV, BiPAP-ST, supplemental oxygen.
Efficacy of Surgical Interventions	Effective in selected anatomies (UPPP, maxillomandibular advancement, hypoglossal stimulation).	No clinical efficacy for airway surgeries; phrenic nerve stimulation implants utilized instead.

4.4 First-Line Therapeutic Approaches

Because the underlying physiological drivers are fundamentally different, treating Obstructive Sleep Apnea with therapies designed for Central Sleep Apnea—or vice versa—can lead to poor outcomes. For Obstructive Sleep Apnea, the gold-standard first-line treatment remains Continuous Positive Airway Pressure (CPAP). CPAP works as a pneumatic splint. It delivers a column of pressurized ambient air through a nasal, pillow, or full-face interface, elevating intraluminal pharyngeal pressure above the patient’s critical closing pressure (Pcrit). This pushes the soft palate, tongue base, and pharyngeal lateral walls outward, stenting the airway open and eliminating flow limitation, snoring, and paradoxical respiratory effort.

In contrast, using standard CPAP to treat non-hypercapnic Central Sleep Apnea is often ineffective. Because the upper airway is already patent in pure CSA, applying static pneumatic pressure does not address the underlying issue: an unstable brainstem ventilatory drive. In fact, standard CPAP can paradoxically worsen central apneas. By lowering upper airway resistance, it can increase alveolar ventilation, wash out carbon dioxide, and drive PaCO₂ further below the apneic threshold. Furthermore, lung inflation stimulated by positive pressure can trigger pulmonary stretch receptors (the Hering-Breuer reflex), which inhibits central inspiratory drive and can increase the frequency of central apneas.

Managing Central Sleep Apnea requires targeted physiological stabilization. First-line therapy focuses on optimizing the underlying medical conditions driving the respiratory instability. In Cheyne-Stokes breathing, the primary intervention is aggressive, guideline-directed medical therapy (GDMT) for congestive heart failure. Implementing neurohormonal blockade—using Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), beta-blockers, Mineralocorticoid Receptor Antagonists (MRAs), and Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors—improves left ventricular ejection fraction, lowers pulmonary capillary wedge pressure, reduces pulmonary congestion, and shortens circulatory delay. This dampens loop gain and can resolve central sleep apnea without positive airway pressure therapy.

When positive airway pressure is required for CSA, specialized ventilatory modalities are used. The most advanced modality is Adaptive Servo-Ventilation (ASV). ASV monitors the patient’s minute ventilation on a breath-by-breath basis. During the hyperpneic crescendo phase, the device reduces pressure support to prevent over-ventilation and carbon dioxide washout. When the patient begins to hypoventilate or slips into a central apnea, the device increases pressure support, smoothly stepping in to deliver a target ventilation volume based on the patient’s recent baseline. In patients with drug-induced CSA or central hypoventilation who retain carbon dioxide, Bi-level Positive Airway Pressure with a Timed backup rate (BiPAP-ST) is preferred. This modality guarantees a minimum number of mandatory breaths per minute if the patient’s central drive stops entirely.

Non-PAP interventions also differ fundamentally between the two conditions. For anatomical OSA, therapies include:

• Mandibular Advancement Devices (MADs) that draw the lower jaw forward to clear the retroglossal space
• Upper airway soft tissue or skeletal surgery (such as Maxillomandibular Advancement)
• Hypoglossal nerve stimulation, which rhythmically contracts the genioglossus muscle during inspiration

None of these anatomical approaches have any therapeutic role in pure Central Sleep Apnea. Conversely, targeted therapies for CSA—such as low-flow nocturnal oxygen therapy (which dampens carotid body controller gain) or transvenous phrenic nerve stimulation—are designed to stabilize ventilatory neurobiology rather than modify physical airway geometry.

5. Similarities and Clinical Overlap

5.1 Shared Pathological Sequelae

Despite their distinct pathophysiological origins, Obstructive and Central Sleep Apnea share common molecular, cellular, and cardiovascular consequences. Both disorders subject the body to cycles of intermittent hypoxia and reoxygenation, which act as potent triggers for oxidative stress. The rapid drop in arterial oxygen saturation, followed by sudden reoxygenation at event termination, overburdens mitochondrial electron transport chains, generating bursts of reactive oxygen species (ROS) such as superoxide anions and hydrogen peroxide.

These reactive oxygen species activate transcription factors, particularly Nuclear Factor Kappa B (NF-κB) and Hypoxia-Inducible Factor 1-alpha (HIF-1α). This activation upregulates downstream inflammatory cascades, elevating circulating levels of systemic inflammatory markers including high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and intercellular adhesion molecule-1 (ICAM-1). The resulting systemic inflammatory state causes vascular endothelial dysfunction, uncouples endothelial nitric oxide synthase (eNOS), reduces nitric oxide bioavailability, and accelerates systemic atherosclerosis.

Autonomic dysregulation represents another shared pathological pathway. Both obstructive struggles and the crescendo-decrescendo cycles of central periodic breathing trigger intense bursts of sympathetic nerve activity (SNA). In OSA, sympathetic surges are driven by carotid body stimulation and the emotional stress of suffocating against a physical barrier. In CSA, sympathetic surges occur during the hyperpneic recovery phase, driven by elevated chemoreceptor activation and cortical microarousals. In both conditions, this nocturnal sympathetic overdrive persists into the daytime hours. This persistent autonomic tone causes vascular vasoconstriction, sustains systemic hypertension, activates the renin-angiotensin-aldosterone system (RAAS), and promotes cardiac remodeling.

The downstream clinical consequences of this shared autonomic and inflammatory cascade are severe. Both OSA and CSA significantly increase the incidence of cardiac arrhythmias, particularly atrial fibrillation. Rapid fluctuations in autonomic tone, combined with atrial stretch and myocardial hypoxia, create an ideal substrate for arrhythmogenesis. Both conditions are associated with higher rates of coronary artery disease, ST-segment elevation myocardial infarctions, ischemic strokes, and sudden cardiac death. Neurocognitively, both disorders degrade executive function, working memory, and emotional regulation. Repeated microarousals disrupt sleep architecture, preventing the slow-wave sleep required for restorative function and impairing glymphatic clearance of neurotoxic metabolic waste products, such as amyloid-beta, from the central nervous system.

5.2 Treatment-Emergent Central Sleep Apnea

The boundary between mechanical and neurological sleep-disordered breathing can blur during clinical management. The clearest example of this overlap is Treatment-Emergent Central Sleep Apnea (TECSA), historically referred to as Complex Sleep Apnea. TECSA describes a phenomenon where a patient undergoes polysomnography and shows predominantly obstructive sleep apnea, but upon application of continuous positive airway pressure (CPAP), the obstructive events resolve, only for repetitive, clinically significant central apneas to emerge or worsen.

Under the AASM diagnostic criteria, TECSA is diagnosed when a patient demonstrates an obstructive-predominant baseline study, but during CPAP titration (or home CPAP use), their obstructive events clear while their Central Apnea Index (CAI) rises to ≥5 events per hour, or central events account for ≥50% of the total residual Apnea-Hypopnea Index. This phenomenon occurs in approximately 5% to 15% of all patients initiated on positive airway pressure therapy for OSA. It often frustrates patients and clinicians alike, as the patient continues to experience fragmented sleep despite using an effective mechanical splint.

The pathophysiology of TECSA is driven by a combination of unmasked high loop gain and positive-pressure mechanics. Many patients with severe obstructive sleep apnea develop an elevated central controller gain due to chronic nocturnal hypoxia and hypercapnia. When CPAP splints the airway open, several physiological shifts occur:

• Airway resistance drops immediately, allowing alveolar ventilation to increase.
• This surge in ventilation washes out carbon dioxide, driving PaCO₂ below the patient’s individual apneic threshold.
• If the CPAP pressure is set too high, involuntary lung hyperinflation can activate the Hering-Breuer reflex, sending inhibitory signals along vagal afferents to the brainstem to pause breathing.
• Frequent arousals, often triggered by an uncomfortable mask interface or pressure leaks, cause ventilatory overshoots, continuing the cycle of central apneas.

Fortunately, the natural history of treatment-emergent central sleep apnea is largely benign and self-limiting. Longitudinal clinical trials have shown that with continued, compliant CPAP use, TECSA spontaneously resolves in 60% to 80% of patients within 8 to 12 weeks. Over this period, the brain’s chemoreceptors adapt to the new, stabilized gas exchange environment, resetting the apneic threshold and stabilizing loop gain. For the remaining 20% to 30% of patients in whom TECSA persists, clinical intervention is required. This may involve lowering the continuous pressure, turning off aggressive pressure-relief settings, switching to Adaptive Servo-Ventilation (ASV), or introducing temporary pharmacotherapy to stabilize loop gain.

5.3 Mixed Sleep Apnea Episodes

The overlap between mechanical and neurological pathology is also evident in individual respiratory events termed mixed sleep apneas. A mixed apnea is a single respiratory event that contains both central and obstructive components within its duration. Under AASM scoring guidelines, a mixed apnea begins as a central event characterized by an initial absence of both airflow and thoracoabdominal effort, but concludes as an obstructive event, with respiratory effort resuming against a closed pharyngeal airway before airflow is finally restored.

The mechanics of a mixed apnea highlight the interplay between central nervous signaling and pharyngeal collapsibility. During the initial central phase, the brainstem stops sending motor commands to the diaphragm and intercostal muscles. Crucially, the motor output to the upper airway dilators—including the hypoglossal nerve driving the genioglossus muscle—is also withdrawn during this central pause. As a result, the muscular pharynx relaxes and falls inward. By the time carbon dioxide accumulates sufficiently to stimulate the central chemoreceptors and reactivate diaphragmatic breathing, the upper airway has already collapsed. When the diaphragm begins contracting again, it pulls against an occluded tube, transforming what began as a neurological pause into a mechanical obstruction.

Accurate identification of mixed apneas is essential for clinical decision-making. If a polysomnogram reveals that a high overall Apnea-Hypopnea Index is driven primarily by mixed apneas, the treatment approach mirrors that of obstructive sleep apnea rather than central sleep apnea. Because the concluding phase of the event involves an obstructive collapse that prevents ventilation, applying positive airway pressure (CPAP) to pneumatically stent the pharynx typically resolves both phases. By preventing airway collapse during the central pause, CPAP allows ventilation to resume smoothly as soon as central drive returns, preventing the secondary obstructive struggle.

6. Clinical Guidance: Diagnostic Differentiation and Treatment Selection

6.1 Diagnostic Workup and Polysomnography Interpretation

Accurate differentiation between Obstructive Sleep Apnea, Central Sleep Apnea, and mixed presentations requires a structured diagnostic approach centered on comprehensive physiological monitoring. While Home Sleep Apnea Testing (HSAT)—specifically Type 3 and Type 4 diagnostic monitors—has expanded access to care, these simplified systems possess limitations when evaluating non-obstructive sleep-disordered breathing. Most Type 3 home monitors track only four physiological channels: airflow (via a nasal pressure cannula), arterial oxygen saturation (pulse oximetry), heart rate, and a single chest effort band (usually a basic z-axis accelerometer or single piezo sensor).

Relying on home sleep tests to evaluate suspected Central Sleep Apnea can lead to misclassification. Without concurrent electroencephalography (EEG), electrooculography (EOG), and submental electromyography (EMG), an HSAT device cannot determine whether a patient is asleep or awake. If a patient with severe insomnia lies awake in bed with shallow, irregular breathing, an automated HSAT algorithm may miscalculate those periods of quiet wakefulness as central apneas, artificially inflating the central apnea index. Conversely, single-belt chest effort monitors lack the sensitivity required to distinguish paradoxical thoracoabdominal effort from true absence of effort, leading to misclassification of obstructive events as central, or vice versa. Therefore, professional guidelines recommend attended, in-laboratory Type 1 Polysomnography whenever Central Sleep Apnea, Cheyne-Stokes breathing, neuromuscular hypoventilation, or severe cardiopulmonary disease is clinically suspected.

Interpreting a Type 1 PSG tracing requires a systematic, multichannel approach:

• First, analyze the dual Respiratory Inductance Plethysmography (RIP) belts placed across the rib cage and abdomen. RIP technology measures cross-sectional changes in volume via sinusoidal alternating current passed through insulated wires sewn into elastic bands, providing an accurate, calibrated measurement of breathing effort.
• Examine the phase angle between the thoracic and abdominal belts. In phase-locked synchronization (0-degree phase shift), both bands move in the same direction, indicating an open airway. In paradoxical breathing (approaching a 180-degree phase shift), the bands move in opposite directions, confirming an obstructive event.
• A complete flatline on both RIP channels—with the phase angle collapsing due to zero movement—confirms a central event.

Next, evaluate the cycle length and the relationship between ventilatory phase and oxygen desaturation. In Cheyne-Stokes breathing, the diagnostic criteria require:

• The presence of at least three consecutive cycles of cyclical crescendo-decrescendo breathing patterns.
• Either a Central Apnea-Hypopnea Index of ≥5 events per hour, or the cyclic pattern persisting for at least 10 consecutive minutes of recording.
• A cycle duration typically lasting 40 to 120 seconds.

Confirming this pattern requires careful inspection of the systemic arterial oxygen saturation curve, which displays sinusoidal oscillations that mirror the crescendo-decrescendo breathing with an offset dictated by the patient’s circulatory delay.

6.2 Positive Airway Pressure Modality Selection

Selecting the appropriate positive airway pressure modality requires matching device mechanics to the underlying pathophysiology. Continuous Positive Airway Pressure (CPAP) remains the initial choice for uncomplicated Obstructive Sleep Apnea. By providing a fixed, continuous pressure, CPAP normalizes functional residual capacity and keeps the pharyngeal walls stented open throughout both inspiration and expiration.

When Central Sleep Apnea is identified, the treatment pathway shifts based on baseline carbon dioxide levels and cardiac function. For patients with hypercapnic central sleep apnea—such as those with neuromuscular disease, amyotrophic lateral sclerosis, cervical spinal cord trauma, or obesity hypoventilation—standard CPAP is insufficient. These patients suffer from inadequate minute ventilation. They require Bi-level Positive Airway Pressure with a Timed backup rate (BiPAP-ST). This device cycles between two distinct pressures:

• An elevated Inspiratory Positive Airway Pressure (IPAP) that assists the weakened musculature in taking a full tidal volume
• A lower Expiratory Positive Airway Pressure (EPAP) that maintains upper airway patency

The essential feature is the “Timed” backup rate: if the patient’s brainstem fails to initiate a spontaneous breath within a preset time window, the device triggers an IPAP cycle, delivering a mandatory mechanical breath and preventing carbon dioxide retention.

For patients with non-hypercapnic central sleep apnea, including idiopathic CSA, treatment-emergent CSA, and Cheyne-Stokes breathing, Adaptive Servo-Ventilation (ASV) is the most effective positive pressure modality. ASV devices use sophisticated algorithms to calculate a moving target minute ventilation, typically based on 90% of the patient’s recent average. When the patient’s breathing waxes during the hyperpneic crescendo, the ASV device lowers its pressure support to a preset minimum, preventing the hyperventilation that washes out carbon dioxide. When breathing wanes during the decrescendo, or stops completely in a central apnea, the device increases pressure support, providing the airflow needed to stabilize minute ventilation and suppress the oscillation.

However, the clinical use of Adaptive Servo-Ventilation is subject to a critical safety contraindication. The landmark SERVE-HF clinical trial (Cowie et al., 2015) evaluated the use of ASV in patients with symptomatic chronic heart failure with reduced ejection fraction (NYHA class II-IV, LVEF ≤ 45%) and predominant central sleep apnea. The trial revealed a statistically significant increase in both all-cause mortality (hazard ratio = 1.28) and cardiovascular mortality (hazard ratio = 1.34) in the group randomized to ASV compared to the control group receiving optimized medical therapy alone. While the exact biological mechanism driving this excess mortality remains debated—hypotheses point to sudden arrhythmogenesis induced by positive intrathoracic pressures in dilated, failing hearts—the clinical takeaway is absolute:

CRITICAL CLINICAL CONTRAINDICATION: Adaptive Servo-Ventilation (ASV) is strictly contraindicated in patients with symptomatic, chronic heart failure with reduced ejection fraction (HFrEF) and a Left Ventricular Ejection Fraction (LVEF) ≤ 45%. Prior to initiating ASV for any form of central sleep apnea, an objective echocardiographic assessment of left ventricular ejection fraction is mandatory.

In patients with HFrEF (≤ 45%) and Cheyne-Stokes breathing, positive pressure options are limited. Management focuses on optimizing guideline-directed medical therapy, with nocturnal supplemental oxygen serving as a safe, non-PAP alternative to suppress loop gain.

6.3 Non-PAP Therapies and Multidisciplinary Management

While positive airway pressure remains common in sleep medicine, long-term patient adherence to CPAP and BiPAP ranges between 50% and 70%. Consequently, non-PAP therapies tailored to specific sleep apnea phenotypes play an important role in comprehensive care.

For patients with mild to moderate Obstructive Sleep Apnea, or those with severe OSA who cannot tolerate CPAP, non-PAP anatomical interventions offer effective alternatives:

• Mandibular Advancement Devices (MADs): Custom-fabricated oral appliances worn over the dental arches during sleep. By mechanically protruding the mandible forward by several millimeters, MADs tighten the palatoglossus and palatopharyngeus muscles, pulling the base of the tongue away from the posterior pharyngeal wall and stabilizing the lateral pharyngeal margins.
• Hypoglossal Nerve Stimulation: An established surgical therapy for moderate-to-severe OSA. A surgically implanted pulse generator, placed beneath the clavicle, connects to a respiratory sensing lead in the intercostal space and a stimulation cuff around the medial branch of the hypoglossal nerve (Cranial Nerve XII). The system senses the onset of inspiration and delivers a mild electrical impulse to the nerve fibers innervating the genioglossus, causing the tongue to gently protrude forward in sync with breathing. Candidacy requires an AHI between 15 and 65, a BMI < 35 or 40 kg/m² (depending on regulatory jurisdiction), and the absence of complete concentric collapse of the soft palate on Drug-Induced Sleep Endoscopy (DISE).

For Central Sleep Apnea, non-PAP management requires a different, multidisciplinary strategy centered on cardiology and neurostimulation:

• Cardiovascular Optimization: The primary intervention for Cheyne-Stokes CSA is optimizing heart failure management. Revascularization, cardiac resynchronization therapy (CRT), and optimized guideline-directed medical therapy have been shown to reduce Cheyne-Stokes respiration by improving forward cardiac output, lowering pulmonary capillary pressures, and stabilizing circulatory transit time.
• Transvenous Phrenic Nerve Stimulation: A targeted non-PAP neurostimulation platform developed for moderate-to-severe Central Sleep Apnea (the remedē system). A transvenous implantable neurostimulator is positioned subcutaneously in the pectoral pocket. A transvenous lead is advanced into either the left pericardiophrenic vein or the right brachiocephalic vein, positioning electrodes adjacent to the phrenic nerve. The device activates automatically at night, delivering mild electrical pulses to the phrenic nerve to induce smooth, physiological contractions of the diaphragm, restoring regular minute ventilation without requiring an external mask or positive pressure. Clinical trials have demonstrated sustained reductions in the Central Apnea Index, improved oxygen saturation profiles, and gains in quality of life without adverse impacts on heart failure mortality.

7. Frequently Asked Questions

7.1 Can Obstructive Sleep Apnea Transition into Central Sleep Apnea?

Yes, Obstructive Sleep Apnea can transition into a central sleep apnea presentation, a phenomenon known as Treatment-Emergent Central Sleep Apnea (TECSA) or complex sleep apnea. This transition typically occurs when positive airway pressure (CPAP) is applied to treat obstructive events. When the physical obstruction is resolved, ventilation increases, and carbon dioxide is washed out of the blood. If the patient has sensitive chemoreceptors (high loop gain), this reduction in PaCO₂ drops their carbon dioxide levels below their individual apneic threshold, triggering central apneas.

Additionally, long-standing, severe OSA can cause neurological remodeling within brainstem respiratory networks due to years of intermittent hypoxia and recurrent microarousals. This remodeling can destabilize the chemoreceptive reflex arc. When the mechanical resistance is removed by CPAP, this latent ventilatory instability is unmasked. Fortunately, true phenotypic transitions in untreated patients are rare. In most cases, TECSA reflects either an unmasking of baseline ventilatory instability or a temporary adaptation to positive pressure, which resolves spontaneously within two to three months of consistent CPAP use.

7.2 Why Is Adaptive Servo-Ventilation (ASV) Contraindicated in Some CSA Patients?

Adaptive Servo-Ventilation is contraindicated in patients with symptomatic, chronic heart failure with reduced ejection fraction (HFrEF) and a Left Ventricular Ejection Fraction (LVEF) ≤ 45%. This contraindication stems from the multicenter, randomized controlled SERVE-HF trial (Cowie et al., 2015). The trial sought to determine whether eliminating Cheyne-Stokes central sleep apnea with ASV would improve cardiovascular outcomes in patients with heart failure. Instead, the study found a statistically significant increase in both all-cause mortality and cardiovascular death among patients treated with ASV compared to the control group.

While the precise mechanisms continue to be studied, researchers hypothesize that Cheyne-Stokes breathing may serve as an adaptive physiological response in advanced heart failure, protecting failing cardiomyocytes from sympathetic stress, or that applying dynamic, positive intrathoracic pressures in dilated, failing ventricles impairs preload, reduces cardiac output, and triggers fatal ventricular arrhythmias. As a result, professional guidelines worldwide prohibit ASV in patients with an LVEF ≤ 45%. However, ASV remains approved, safe, and effective in patients with central sleep apnea who have preserved cardiac function (LVEF > 45%), such as those with idiopathic CSA, stroke-related CSA, or persistent treatment-emergent central sleep apnea.

7.3 Is Snoring a Reliable Differentiating Symptom Between OSA and CSA?

While snoring is a valuable clinical sign, it is not an absolute diagnostic discriminator. Heavy, disruptive, chronic snoring is highly sensitive for Obstructive Sleep Apnea, present in up to 90% to 95% of patients with moderate to severe disease. Snoring represents the audible vibration of the soft palate and pharyngeal lateral walls as air moves through a narrowed, structurally compromised conduit. In pure Central Sleep Apnea, the upper airway remains patent, and air movement stops entirely due to the absence of diaphragmatic effort, meaning pure CSA is characteristically quiet.

However, relying solely on snoring history can lead to clinical errors. First, patients with mixed sleep apnea frequently snore during the obstructive phases of their sleep, which can mask the underlying central apneas occurring throughout the night. Second, patients with Cheyne-Stokes central sleep apnea may produce loud breathing or snorting noises during the rapid, hyperpneic recovery phase of their cycle, which bedpartners often mischaracterize as classic snoring. Finally, elderly patients with severe OSA may lose the ability to generate loud snoring sounds due to muscular atrophy and age-related changes in pharyngeal tissue. Therefore, while the absence of any snoring history should raise clinical suspicion for central sleep apnea or an alternative disorder, an objective polysomnogram is required for confirmation.

7.4 Which Condition Carries a Worse Long-Term Prognosis?

Determining which condition carries a worse prognosis depends primarily on the patient’s underlying comorbidities. In general clinical practice, Central Sleep Apnea is associated with a significantly higher short-to-medium-term mortality rate than Obstructive Sleep Apnea. However, this is largely because CSA functions as a physiological biomarker of advanced systemic disease, particularly decompensated heart failure, severe stroke, or advanced renal failure. The emergence of Cheyne-Stokes respiration in a patient with congestive heart failure is an independent predictor of worsening cardiac function and elevated mortality.

Obstructive Sleep Apnea, by contrast, is a chronic driver of progressive disease. Untreated severe OSA leads to significant morbidity over decades, steadily accelerating the development of drug-resistant hypertension, coronary atherosclerosis, Type 2 diabetes, atrial fibrillation, and stroke. However, the immediate mortality risk in uncomplicated OSA is lower than that seen in heart failure-associated CSA. Fortunately, when OSA is consistently treated with CPAP, oral appliances, or surgical intervention, its long-term cardiovascular and metabolic risks can be substantially mitigated. In CSA, long-term prognosis depends primarily on how effectively the underlying cardiac or neurological disease can be managed.

8. Conclusion: Synthesizing the Management of Sleep-Disordered Breathing

8.1 Summary of Core Distinctions

Obstructive Sleep Apnea and Central Sleep Apnea represent fundamentally different failures within human respiratory physiology. OSA is an anatomical, mechanical disorder characterized by recurrent collapse of the pharyngeal airway despite ongoing, paradoxical respiratory effort. It is driven by airway geometry, tissue mass, and muscular collapsibility (Pcrit), and presents with loud snoring, witnessed choking, and daytime hypersomnolence. In contrast, CSA is a neurobiological disorder of ventilatory control characterized by the transient cessation of central motor output from the brainstem, with a complete absence of respiratory effort. It is driven by chemoreceptor instability (high loop gain), low baseline carbon dioxide relative to the apneic threshold, and prolonged circulatory transit times.

Accurate differentiation between these two conditions requires objective polysomnography. While OSA responds reliably to mechanical stenting via Continuous Positive Airway Pressure, mandibular repositioning, and hypoglossal stimulation, pure CSA requires stabilizing ventilatory loop gain through guideline-directed cardiovascular therapy, adaptive servo-ventilation (in patients with LVEF > 45%), or transvenous phrenic nerve stimulation. Conflating these entities can compromise patient safety, as illustrated by the contraindication of ASV in patients with reduced ejection fraction heart failure.

8.2 Future Perspectives in Sleep Medicine

The field of sleep medicine is moving rapidly toward personalized, precision therapeutics. The traditional diagnostic reliance on the Apnea-Hypopnea Index alone is giving way to physiological “endotyping.” By using mathematical modeling of routine polysomnographic data, clinicians can now quantify an individual’s specific physiological traits: their mechanical collapsibility (Pcrit), their arousal threshold, their loop gain, and their muscle responsiveness.

This physiological endotyping is opening new avenues for targeted non-PAP therapies. Patients with obstructive sleep apnea who demonstrate high loop gain as a primary trait may benefit from combination therapy pairing oral appliances with carbonic anhydrase inhibitors (such as acetazolamide) to stabilize chemical drive. Novel pharmacotherapies—including combinations of norepinephrine reuptake inhibitors and antimuscarinics designed to increase hypoglossal motor output during sleep—are advancing through late-phase clinical trials. Simultaneously, advances in implantable neurostimulation platforms, from bilateral hypoglossal stimulators to transvenous phrenic nerve activators, are expanding options for patients who cannot tolerate positive airway pressure. Ultimately, moving beyond a one-size-fits-all model toward precision, mechanism-based care will ensure that both mechanical and neurological sleep-related breathing disorders are diagnosed accurately and treated safely.

References

• American Academy of Sleep Medicine. (2014). International Classification of Sleep Disorders (3rd ed.). American Academy of Sleep Medicine.
• Benjafield, A. V., Ayas, N. T., Eastwood, P. R., Heinzer, R., Ip, M. S. M., Patel, S. R., Peppard, P. E., Sinha, P. R., Tufik, S., Valentine, K., & Malhotra, A. (2019). Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis. The Lancet Respiratory Medicine, 7(8), 687–698. https://doi.org/10.1016/S2213-2600(19)30198-5
• Berry, R. B., Budhiraja, R., Gottlieb, D. J., Gozal, D., Iber, C., Kapur, V. K., Marcus, C. L., Mehra, R., Parthasarathy, S., Quan, S. F., Redline, S., Strohl, K. P., Davidson Ward, S. L., & Tangredi, M. M. (2012). Rules for scoring respiratory events in sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Journal of Clinical Sleep Medicine, 8(5), 597–619. https://doi.org/10.5664/jcsm.2172
• Cowie, M. R., Woehrle, H., Wegscheider, K., Angermann, C., d’Ortho, M. P., Erdmann, E., Levy, P., Simonds, A. K., Somers, V. K., Zannad, F., & Teschler, H. (2015). Adaptive servo-ventilation for central sleep apnea in systolic heart failure. The New England Journal of Medicine, 373(12), 1095–1105. https://doi.org/10.1056/NEJMoa1506459
• Eckert, D. J., White, D. P., Jordan, A. S., Malhotra, A., & Wellman, A. (2013). Defining phenotypic causes of obstructive sleep apnea: Identification of novel therapeutic targets. American Journal of Respiratory and Critical Care Medicine, 188(8), 996–1004. https://doi.org/10.1164/rccm.201303-0448OC
• Javaheri, S., Barbe, F., Campos-Rodriguez, F., Dempsey, J. A., Khayat, R., Javaheri, S., Malhotra, A., Martinez-Garcia, M. A., Mehra, R., Pack, A. I., Polotsky, V. Y., Somers, V. K., & Schwab, R. J. (2017). Sleep apnea: Types, mechanisms, and clinical cardiovascular consequences. Journal of the American College of Cardiology, 69(7), 841–858. https://doi.org/10.1016/j.jacc.2016.11.069
• Kapur, V. K., Auckley, D. H., Chowdhuri, S., Kuhlmann, D. C., Mehra, R., Ramar, K., & Harrod, C. G. (2017). Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(3), 479–504. https://doi.org/10.5664/jcsm.6506
• Malhotra, A., & White, D. P. (2002). Obstructive sleep apnoea. The Lancet, 360(9328), 237–245. https://doi.org/10.1016/S0140-6736(02)09464-3
• Peppard, P. E., Young, T., Barnet, J. H., Palta, M., Hagen, E. W., & Hla, K. M. (2013). Increased prevalence of sleep-disordered breathing in adults. American Journal of Epidemiology, 177(9), 1006–1014. https://doi.org/10.1093/aje/kws342
• Somers, V. K., White, D. P., Amin, R., Abraham, W. T., Costa, F., Culebras, A., Daniels, S., Floras, J. S., Javaheri, S., Marks, P., Pankow, J., Parthasarathy, S., Patterson, R., Redline, S., Schwab, R. J., & Teschler, H. (2008). Sleep apnea and cardiovascular disease: An American Heart Association/American College of Cardiology Foundation scientific statement. Circulation, 118(10), 1080–1111. https://doi.org/10.1161/CIRCULATIONAHA.108.190130
• Stanchina, M. L., Welschenbach, M., & Malhotra, A. (2013). Emergence of central sleep apnea during positive airway pressure therapy. Chest, 144(4), 1403–1408. https://doi.org/10.1378/chest.12-2592
• Wellman, A., Jordan, A. S., Malhotra, A., Fogel, R. B., Katz, E. S., Schory, K., Edwards, J. K., & White, D. P. (2004). Ventilatory control and airway anatomy in obstructive sleep apnea. American Journal of Respiratory and Critical Care Medicine, 170(11), 1225–1232. https://doi.org/10.1164/rccm.200404-510OC